On the 9th, GC Biopharma announced that it had signed a follow-up joint research agreement with Dong-A ST to develop mRNA-LNP-based new drugs for chronic inflammatory diseases

The companies had jointly selected new drug targets for chronic inflammatory diseases in October last year after forging a collaboration agreement that covers the joint research and development of novel modalities.

The follow-up agreement will further identify mechanisms of action (MOAs) for drug targets selected last year and evaluate their efficacy and safety in preclinical models.

GC Biopharma will synthesize mRNAs that can act on select targets, and screen and optimize LNPs that can be delivered